Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q3 2014 · 10-Q
Revenue$137.95M$137.95M+54.8% vs Q3 2013 Net Income$21.83M$21.83M+61.8% vs Q3 2013 EPS Diluted$0.49$0.49+36.1% vs Q3 2013 Operating Income$31,032,000+71.0% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$73,702,000+85.1% Margins · derivedOperating margin22.5%+2.1 pt vs Q3 2013
Net margin15.8%+0.7 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 10, 2014 · 41 d after period end